Aidoc stock
Private-market facts for current and former Aidoc employees researching their stock.
Overview
Aidoc develops AI-powered medical imaging analysis software that helps radiologists prioritize and diagnose critical conditions like strokes, pulmonary embolisms, and fractures from CT scans.
Aidoc outlook
For employees evaluating Aidoc equity, a 1x base multiple suggests the stock may be close to fairly valued at current prices. The upside scenario at 2x is relatively close to the base case, suggesting more predictable but narrower range of outcomes.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling Aidoc shares
Why shareholders consider selling
Shareholders in Aidoc may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Aidoc does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Aidoc stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Aidoc shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Aidoc shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series D round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Aidoc shareholders
Exploring equity in Aidoc often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Aidoc most recently raised a Series D round . Total funding raised to date is approximately $250M.
Lead investors in this round include General Catalyst.
Founders & company background
Aidoc was founded in 2016 by Elad Walach, Michael Braginsky, Guy Reiner and is headquartered in Tel Aviv, Israel.
Investors
Industry
Similar private companies
Frequently asked questions
- Is Aidoc still a private company?
- Yes, Aidoc is currently a private company.
- What is Aidoc's latest funding round?
- Aidoc's most recent known round is Series D.
- What is Aidoc's valuation?
- Aidoc's valuation has not been publicly disclosed.
- Who are the investors in Aidoc?
- Notable investors include General Catalyst.
- Can I sell my Aidoc stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Aidoc stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Aidoc data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.